Neurotech focuses on ophthalmics:
This article was originally published in Clinica
Executive Summary
Private French company Neurotech is to concentrate exclusively on developing ophthalmic technologies and has stopped its early-stage R&D efforts into neuroscience and cell therapy. The Evry-based company's decision is based on promising technological developments by its US subsidiary into encapsulated cell technology (ECT), a means of delivering drugs across the blood-retina barrier.